Brasília – A federal appellate judge affirmed there was no conflict of interest in his decision to suspend the patent extension for liraglutide (Victoza and Saxenda). The judge refuted claims suggesting bias or personal ties to pharmaceutical companies, stating that the ruling was independent and grounded purely in legal and technical considerations.

The decision overturns an earlier extension meant to compensate for delays at the National Industrial Property Institute (INPI). The judge emphasized that his judgment was based solely on principles of fair competition and protection of public health, given the consequences of extended exclusivity for the SUS.

Source: JOTA

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com